Expands management team as company pursues new growth opportunities

CAMBRIDGE, MA – January 9, 2012 – Knome, Inc., the human genome interpretation company, today announced that it has appointed Martin Tolar, MD, PhD, as the company’s Chief Executive Officer. In addition, Knome has expanded the management team as the company pursues new growth opportunities to interpret and apply genomic information across the healthcare community—including academic researchers, drug companies, physicians, and consumers. Continue reading →

Knome’s informatics and software tools to be used to interpret whole genomes of African American and African Caribbean asthma patients

CAMBRIDGE, MA – January 9, 2012 – Knome, Inc., the human genome interpretation company, today announced that it has been awarded a contract by the Johns Hopkins University School of Medicine. Under the agreement, Knome will supply its informatics services and software tools to Johns Hopkins’ landmark study to uncover genetic variants that contribute to asthma in African American and African Caribbean populations. The 1,000 genomes in the study will come from participants of African descent from 15 academic research centers across the United States, the Caribbean, and South America—as well as from four additional research sites in Western Africa.

In addition to annotating the genomes in the study, Knome’s informatics platform will transform each genome’s raw sequence information into a dataset suitable for comparative interpretation. Knome’s advanced software tools, including knomeVARIANTS and knomePATHWAYS, will then be used by Johns Hopkins researchers to shortlist candidate causal variants, genes, and gene networks. Continue reading →

David Goldstein and Dr. Yaniv Erlich bring genomics expertise
as company pursues future growth

CAMBRIDGE, MA – January 9, 2012 – Knome, Inc., the human genome interpretation company, today announced that it has expanded its scientific advisory board to include two respected experts in genomics, Dr. David Goldstein of Duke University and Dr. Yaniv Erlich of the Whitehead Institute for Biomedical Research.

“We are very pleased to appoint two highly talented genomics experts to our scientific advisory board as we continue to pursue Knome’s mission of improving lives by applying the scientific insights gained from the interpretation of human genomes,” said Martin Tolar, Chief Executive Officer of Knome. “Drs. Goldstein and Erlich each offer incredibly valuable expertise as we pursue new opportunities in drug development and medicine. We look forward to their contributions this year and into the future.” Continue reading →